Salix Pharmaceuticals Ltd. (Nasdaq: SLXP) has agreed to purchase intellectual property assets of a medication that treats side effects caused by liver failure, in the latest pharmaceutical deal.
Terms of the deal were not disclosed.
Complete access to real-time information and analysis of news and trends in the industry.
14-Day Free Trial
No credit card required. Complete access to articles, breaking news and industry data.
Have an account? Sign In